Icon

Astepro - (EQ 0.1876/0.125 mg; Base/Spray)

Azelastine Hydrochloride Meda pharma
EQ 0.1876/0.125 mg; Base/Spray
Less Than $1000 mn
Less Than 5
More Than 5
Less Than 5
None
More Than 5
More Than 5
Indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 6 months of age and older.
Yes
****** *** ******* *** ****** **** **** ****** '*** (**** **, ****) *** ** ****** **** *** ******* *****. ***** ****** *** ****** (** ********** ****** '***- *** **, ****), ***** & ****** **** ***** **** ** *** ************ ********* ** ****. **** ****** *** ******* ********* ***** ***** ****, *** **** *** *** ********* ** *** ** ******, **** ***** ********* **** *** ****** ** ******** ******* ****** ***** *** ** ****** *** ******* **** ********* ******** *** ******* ******** *** ******* . *** ********** ** ********* **** *** *** ********* ***** *** ***** ** ********* *** *** *****.
Astepro Patent 1 Patent 2 Patent 3
******* ******* ******* *******
****** ******* ******* *******
***** ****** ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ** **** **,**** ******* ******** ******** ** *** *, ****
****** *** \ *** **** **,**** ******* ******** ******** ** *** *, ****
***** ****** ** \ ** *** **,**** ******* **** ****** **** ********
  1. *** **, **** : ****** *** ******* ******** **** ***** ***** **** ** **** ****** '***- **** **, ****.
  2. *** **, **** : **** **** ****** *** ******* ** ******** ***** ** *** ******.
  3. **** **, **** : ****** ******** **** ***** *** **** ** **** ****** '***.
  4. **** **, **** : **** **** ****** ** ******** ***** ** *** ******.
  5. *** **, **** : ****** *** ***** ******** *** *** *** ****** *** *******.
  6. *** **, **** : ********** *** ********* **** ****** ***** ****** ****** **** *** **** ***** ******** ****** '*** *** **** ** **** *** ****** *** ******* **** ****** '*** ** ****** *******.
  7. *** *, **** : ******* ******** ******** *** ******** *** *******.
  8. *** **, **** : ********** *** ********* **** ******* ***** ******* ****** **** *** **** ***** ******** ****** '*** *** **** ** **** *** ****** *** ******* **** ****** '*** ** ****** *******.
  9. *** **, **** : **** ***** * **** ******* ****** & ****** ********** ** *** *** ********* ********** ***** **** ** **** ******* '***- **** **, ****, '***-*** **, ****.
  10. *** *, **** : ***** *** **-**** ******** ********* **** ** ******* '***- **** **, ****, '***-*** **, ****.
  11. *** **, **** : **** **** ***** ** ** ** ********
  12. *** *, **** : ********** *** ********* **** *****, ****** & ****** ***** *** ***** ** ********* *** *** *****.
  13. *** **, **** : **** ***** * **** ******* ********* ** *** *******.
  14. *** *, **** : ********** ********* **** ********* ** *** *******.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.